

Paolo Ceppi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4135122/paolo-ceppi-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45 papers	2,786 citations	26 h-index	48 g-index
48 ext. papers	3,176 ext. citations	7.7 avg, IF	4.9 L-index

#	Paper	IF	Citations
45	3D Hydrogel-based microcapsules as an in vitro model to study tumorigenicity, cell migration and drug resistance.. <i>Acta Biomaterialia</i> , 2022 ,	10.8	2
44	3D Spheroids Versus 3D Tumor-Like Microcapsules: Confinement and Mechanical Stress May Lead to the Expression of Malignant Responses in Cancer Cells. <i>Advanced Biology</i> , 2021 , 5, e2000349		1
43	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2021 , 124, 281-289	8.7	11
42	The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter. <i>Oncogene</i> , 2021 , 40, 2309-2322	9.2	6
41	Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 248	12.8	5
40	A non-proliferative role of pyrimidine metabolism in cancer. <i>Molecular Metabolism</i> , 2020 , 35, 100962	8.8	30
39	Down-Regulation of CK2 Leads to Up-Regulation of the Cyclin-Dependent Kinase Inhibitor p27 in Conditions Unfavorable for the Growth of Myoblast Cells. <i>Cellular Physiology and Biochemistry</i> , 2020 , 54, 1177-1198	3.9	1
38	Polyhydroxyphenylvalerate/polycaprolactone nanofibers improve the life-span and mechanoresponse of human iPSC-derived cortical neuronal cells. <i>Materials Science and Engineering C</i> , 2020 , 111, 110832	8.3	6
37	Targeting EMT in Cancer with Repurposed Metabolic Inhibitors. <i>Trends in Cancer</i> , 2020 , 6, 942-950	12.5	58
36	Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. <i>Cell Death and Differentiation</i> , 2019 , 26, 2223-2236	12.7	19
35	Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells. <i>Cancer Research</i> , 2018 , 78, 1604-1618	10.1	49
34	GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers. <i>Oncogene</i> , 2018 , 37, 1340-1353	9.2	24
33	Characterization and diagnostic application of genomic fusion sequences in anaplastic large-cell lymphoma. <i>Oncotarget</i> , 2018 , 9, 26543-26555	3.3	9
32	CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. <i>Cell Reports</i> , 2017 , 18, 2373-2386	10.6	46
31	Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial-to-mesenchymal transition of cancer cells. <i>Journal of Pathology</i> , 2017 , 242, 221-233	9.4	22
30	The role of CD95 and CD95 ligand in cancer. <i>Cell Death and Differentiation</i> , 2015 , 22, 549-59	12.7	149
29	CD95 and CD95L promote and protect cancer stem cells. <i>Nature Communications</i> , 2014 , 5, 5238	17.4	55

28	MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. <i>Oncogene</i> , 2014 , 33, 269-78	9.2	83
27	Death induced by CD95 or CD95 ligand elimination. <i>Cell Reports</i> , 2014 , 7, 208-22	10.6	47
26	Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2012 , 130, 1777-86	7.5	23
25	MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2012 , 130, 2044-53	7.5	241
24	Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 983-9	3.5	5
23	CD95 is part of a let-7/p53/miR-34 regulatory network. <i>PLoS ONE</i> , 2012 , 7, e49636	3.7	23
22	p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 473-81	8.9	28
21	Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. <i>Oncogene</i> , 2011 , 30, 2888-99	9.2	196
20	Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. <i>Journal of Translational Medicine</i> , 2011 , 9, 100	8.5	43
19	Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. <i>Molecular Cancer Research</i> , 2010 , 8, 1207-16	6.6	267
18	Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1534-9	2.2	136
17	New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS. <i>Advances in Medical Sciences</i> , 2010 , 55, 22-5	2.8	9
16	Emerging role of thymidylate synthase for the pharmacogenomic selection of patients with thoracic cancer. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2010 , 48, 481-2	2	2
15	Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. <i>Cancer Research</i> , 2009 , 69, 3390-6	10.1	54
14	Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy. <i>Clinical Cancer Research</i> , 2009 , 15, 1039-45	12.9	82
13	Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 3066-74	6.1	48
12	Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. <i>Clinical Cancer Research</i> , 2009 , 15, 7547-7552	12.9	60
11	Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. <i>Journal of Pathology</i> , 2009 , 218, 458-66	9.4	35

10	Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. <i>Modern Pathology</i> , 2009 , 22, 709-17	9.8	85
9	Updated clinical information on multitargeted antifolates in lung cancer. <i>Clinical Lung Cancer</i> , 2009 , 10 Suppl 1, S35-40	4.9	23
8	Human ASH1 expression in prostate cancer with neuroendocrine differentiation. <i>Modern Pathology</i> , 2008 , 21, 700-7	9.8	43
7	Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 1059-64	12.9	71
6	Prognostic role of osteopontin expression in malignant pleural mesothelioma. <i>American Journal of Clinical Pathology</i> , 2008 , 130, 58-64	1.9	45
5	Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 583-9	8.9	36
4	Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. <i>Cancer</i> , 2007 , 110, 1321-8	6.4	18
3	Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. <i>Cancer</i> , 2006 , 107, 1589-96	6.4	326
2	ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. <i>Annals of Oncology</i> , 2006 , 17, 1818-25 ^{10.3}		263
1	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer		1